News
Stocktwits on MSN42m
Novo Nordisk Edges Up Premarket As Q2 Wegovy Sales Defy Copycat Threats: Retail Stays Bullish Amid Tariff PressureU.S.-listed shares of Novo Nordisk (NVO) rose 0.5% in early premarket trading Wednesday after the Danish drugmaker reported ...
Danish pharmaceutical giant Novo Nordisk posted a sharp rise in second-quarter net profit Wednesday, but rising competition ...
It’s the most high-profile example yet of a controversial industry practice called preferred pharmacy networks, or PPNs ...
Novo Nordisk , maker of the weight-loss drug Wegovy, has been sued in U.S. court by investors claiming the Danish ...
Muscle and strength loss in human aging, also known as sarcopenia, can result in trouble with balance and walking, according ...
The number of U.S. adults that are aware of GLP-1 drugs used for weight loss, such as Ozempic and Wegovy, has jumped ...
This potential loss of strength when taking Ozempic could be a particular concern for adults over the age of 60 who are at a higher risk of muscle loss and reduced mobility.
When people were randomised to receive either a placebo or Ozempic, they became biologically younger with the latter drug ...
Despite this, one in five young adults who meet the criteria for the drugs are uninsured and one-third denied having a routine place for healthcare.
GLP-1 drugs often cause weight loss because they mimic the GLP-1 hormone the body naturally produces after eating. Appetite ...
Weight loss medications like Wegovy can be life-changing for people living with obesity or excess weight with related health ...
Some of the most recognizable brand names that could be impacted by new tariffs include Ozempic and Wegovy, two injectable ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback